{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:09:20Z","timestamp":1788786560646,"version":"build-2803163510"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Peyronie\u2019s disease (PD) is characterized by fibrotic plaque formation leading to penile curvature. Xiapex\u2019s 2020 withdrawal from Europe eliminated validated intralesional therapies. This study evaluated the efficacy and safety of an intralesional hyaluronic acid-enzymatic mix (Fibrorestil: 0.05% sodium hyaluronate + recombinant collagenase\/lyase\/lipase) added to daily tadalafil and penile traction versus conservative therapy alone in men with stable-phase PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, randomized, open-label, multicenter pilot trial (June 2023-March 2025; ClinicalTrials.gov NCT07341529; HUPHM-85-21) enrolled 38 men with stable PD, palpable plaque, and 30\u00b0\u201390\u00b0 curvature. Group A received three intralesional sessions with plaque tunneling plus Andropenis extender (\u22654\u00a0hours\/day) and tadalafil (2.5-5\u00a0mg\/day). Group B received traction and tadalafil (conservative therapy) alone. Assessments were performed at baseline and week 28. Analyses used intention-to-treat (n\u2009=\u200938) and per-protocol (n\u2009=\u200934) approaches, with Mann\u2013Whitney U tests. Primary outcomes were absolute and relative curvature change (responders \u226515\u00b0 improvement). Secondary outcomes included Peyronie\u2019s Disease Questionnaire (PDQ) changes; IIEF-EF minimal clinically important difference; satisfaction; and Clavien-Dindo adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline curvatures was higher in Group A (60\u00b0 [50;70] vs 45\u00b0 [30;60], P\u2009=\u2009.037) with Group B showing more diabetes, numerically more hourglass deformity and calcified plaques, and shorter disease duration. Per-protocol curvature change was -15.0\u00b0 [-20.0; -10.0] (27.3%; 52.9% responders) in Group A versus 0.0\u00b0 in Group B (P\u2009=\u2009.001); final curvature was comparable (50\u00b0 vs 45\u00b0, P\u2009=\u2009.786). ANCOVA adjusting for baseline curvature showed an adjusted between-group difference of 14.1\u00b0 (P\u2009=\u2009.001). An exploratory multivariable model additionally adjusting for diabetes, calcification, disease duration, and hourglass deformity attenuated this effect (\u22126.1\u00b0, 95% CI \u221217.7 to 5.5; P\u2009=\u2009.288); given the small sample relative to covariates, this estimate is statistically fragile and hypothesis-generating rather than confirmatory. PDQ symptom-bother improved significantly in Group A [-1.5; P\u2009=\u2009.003], with numerical gains in total [-6.0 vs -2.5; P\u2009=\u2009.149] and physical-psychological [-3.5 vs -1.0; P\u2009=\u2009.110] domains. Satisfaction (\u201csatisfied\/very satisfied\u201d) was reported by 70.6% of Group A versus 11.8% of Group B (P\u2009=\u2009.001). Extender adherence &amp;gt;4\u00a0hours\/day predicted response (88.9% vs 12.5%; P\u2009=\u2009.003). Only mild (Clavien-Dindo I) adverse events occurred (36.8% in Group A versus 5.3%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Fibrorestil intralesional therapy demonstrates possible improvements in curvature and patient-reported outcomes versus conservative care in stable-phase PD and appears safe, while conservative care alone showed no meaningful improvement. Given baseline imbalances, small pilot sample size, open-label design, and lack of an equivalent sham injection control, these findings should be considered exploratory and require confirmation in larger randomized trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdag278","type":"journal-article","created":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T11:34:20Z","timestamp":1787484860000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of hyaluronic acid and enzymatic mix intralesional therapy in Peyronie's disease: a prospective, randomized, controlled pilot study of outcomes and patient satisfaction"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2602-2617","authenticated-orcid":false,"given":"Esa\u00fa","family":"Fern\u00e1ndez-Pascual","sequence":"first","affiliation":[{"name":"Department of Andrology and Sexual Medicine, Lyx Institute of Urology, C\u00e1tedra UFV-The Lyx Institution en Salud Urol\u00f3gica, Universidad Francisco de Vitoria , Madrid 28223 ,","place":["Spain"]},{"name":"Department of Urology, La Paz University Hospital and La Paz Hospital Research Institute , Madrid 28046 ,","place":["Spain"]},{"name":"Department of Urology, Hospital Universitario Viamed Santa Elena , Madrid 28003 ,","place":["Spain"]},{"name":"Facultad de Medicina, Universidad Complutense de Madrid , Madrid 28040 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3269-7434","authenticated-orcid":false,"given":"Giuseppe","family":"Maiolino","sequence":"additional","affiliation":[{"name":"Department of Andrology and Sexual Medicine, Lyx Institute of Urology, C\u00e1tedra UFV-The Lyx Institution en Salud Urol\u00f3gica, Universidad Francisco de Vitoria , Madrid 28223 ,","place":["Spain"]},{"name":"Department of Urology, Hospital Universitario Viamed Santa Elena , Madrid 28003 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3293-5639","authenticated-orcid":false,"given":"Luiz Pedro","family":"Palma-Hendges","sequence":"additional","affiliation":[{"name":"Department of Andrology and Sexual Medicine, Lyx Institute of Urology, C\u00e1tedra UFV-The Lyx Institution en Salud Urol\u00f3gica, Universidad Francisco de Vitoria , Madrid 28223 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen S\u00e1nchez","family":"de la Morena","sequence":"additional","affiliation":[{"name":"Department of Urology, La Paz University Hospital and La Paz Hospital Research Institute , Madrid 28046 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2305-598X","authenticated-orcid":false,"given":"Pablo","family":"Solano-Heranz","sequence":"additional","affiliation":[{"name":"Department of Urology, La Paz University Hospital and La Paz Hospital Research Institute , Madrid 28046 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-1663","authenticated-orcid":false,"given":"Luis","family":"Mart\u00ednez-Pi\u00f1eiro","sequence":"additional","affiliation":[{"name":"Department of Urology, La Paz University Hospital and La Paz Hospital Research Institute , Madrid 28046 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-7569","authenticated-orcid":false,"given":"Enrique","family":"Lled\u00f3\u2013Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Andrology and Sexual Medicine, Lyx Institute of Urology, C\u00e1tedra UFV-The Lyx Institution en Salud Urol\u00f3gica, Universidad Francisco de Vitoria , Madrid 28223 ,","place":["Spain"]},{"name":"Department of Urology, Hospital Universitario Viamed Santa Elena , Madrid 28003 ,","place":["Spain"]},{"name":"Facultad de Medicina, Universidad Complutense de Madrid , Madrid 28040 ,","place":["Spain"]},{"name":"Department of Urology, Gregorio Mara\u00f1\u00f3n General University Hospital , Madrid 28007 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2318-9064","authenticated-orcid":false,"given":"Juan Ignacio","family":"Mart\u00ednez-Salamanca","sequence":"additional","affiliation":[{"name":"Department of Andrology and Sexual Medicine, Lyx Institute of Urology, C\u00e1tedra UFV-The Lyx Institution en Salud Urol\u00f3gica, Universidad Francisco de Vitoria , Madrid 28223 ,","place":["Spain"]},{"name":"Department of Urology, Hospital Universitario Viamed Santa Elena , Madrid 28003 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"issue":"3","key":"2026090708272364300_ref1","doi-asserted-by":"publisher","DOI":"10.5534\/WJMH.200065","article-title":"The natural history of Peyronie\u2019s disease","volume":"39","author":"Di","year":"2021","journal-title":"World J Mens Health"},{"key":"2026090708272364300_ref2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.eururo.2025.04.010","article-title":"European Association of Urology guidelines on male sexual and reproductive health: 2025 update on male hypogonadism, erectile dysfunction, premature ejaculation, and Peyronie\u2019s disease","volume":"88","author":"Salonia","year":"2025","journal-title":"Eur Urol"},{"issue":"1","key":"2026090708272364300_ref3","doi-asserted-by":"publisher","DOI":"10.1093\/sxmrev\/qeaf064","article-title":"History of Peyronie\u2019s disease: from early descriptions to modern treatments","volume":"14","author":"Fuell","year":"2026","journal-title":"Sex Med Rev"},{"issue":"1","key":"2026090708272364300_ref4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/J.JURO.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"issue":"1","key":"2026090708272364300_ref5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/JSM.12731","article-title":"Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie\u2019s disease: a phase 3 open-label study","volume":"12","author":"Levine","year":"2015","journal-title":"J Sex Med"},{"issue":"9","key":"2026090708272364300_ref6","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/J.JSXM.2019.06.010","article-title":"Comparative cost-effectiveness of surgery, collagenase clostridium histolyticum, and penile traction therapy in men with Peyronie\u2019s disease in an era of effective clinical treatment","volume":"16","author":"Wymer","year":"2019","journal-title":"J Sex Med"},{"issue":"3","key":"2026090708272364300_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/J.ESXM.2022.100517","article-title":"Cost of Intralesional collagenase clostridium histiolyticum therapy versus surgery for the Management of Peyronie\u2019s disease: a claims-based analysis (2009-2019)","volume":"10","author":"Walton","year":"2022","journal-title":"Sex Med"},{"issue":"5","key":"2026090708272364300_ref8","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/ANDR.12830","article-title":"At what cost is collagenase clostridium histolyticum viable for treating Peyronie\u2019s disease in a public healthcare system?","volume":"8","author":"Harvey","year":"2020","journal-title":"Andrology."},{"issue":"6","key":"2026090708272364300_ref9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/BJU.14784","article-title":"Optimizing collagenase clostridium histolyticum therapy for Peyronie\u2019s disease using a novel approach with percutaneous needle tunnelling","volume":"124","author":"Fern\u00e1ndez-Pascual","year":"2019","journal-title":"BJU Int"},{"issue":"4","key":"2026090708272364300_ref10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/J.SXMR.2017.07.005","article-title":"Collagenase clostridium histolyticum in the treatment of Peyronie\u2019s disease-a review of the literature and a new modified protocol","volume":"5","author":"Abdel Raheem","year":"2017","journal-title":"Sex Med Rev"},{"issue":"10","key":"2026090708272364300_ref11","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/J.JSXM.2018.08.012","article-title":"Sildenafil 25 mg ODT + collagenase clostridium hystoliticum vs collagenase clostridium hystoliticum alone for the management of Peyronie\u2019s disease: a matched-pair comparison analysis","volume":"15","author":"Cocci","year":"2018","journal-title":"J Sex Med"},{"issue":"5","key":"2026090708272364300_ref12","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/J.EURURO.2019.11.019","article-title":"The end of an era: withdrawal of xiapex (clostridium histolyticum collagenase) from the European market","volume":"77","author":"Cocci","year":"2020","journal-title":"Eur Urol"},{"issue":"10","key":"2026090708272364300_ref13","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.3390\/BIOM11101518","article-title":"Hyaluronic acid: a key ingredient in the therapy of inflammation","volume":"11","author":"Marinho","year":"2021","journal-title":"Biomolecules."},{"issue":"4","key":"2026090708272364300_ref14","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/andr.12368","article-title":"Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie\u2019s disease: preliminary results from a prospective, double-blinded, randomized study","volume":"5","author":"Favilla","year":"2017","journal-title":"Andrology."},{"issue":"2","key":"2026090708272364300_ref15","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6051.25.06662-5","article-title":"Effectiveness of hyaluronic acid in the treatment of Peyronie\u2019s disease in the light of the European urology guidelines: the real-world experience","volume":"78","author":"Zucchi","year":"2026","journal-title":"Minerva Urology and Nephrology."},{"key":"2026090708272364300_ref16","doi-asserted-by":"publisher","first-page":"929367","DOI":"10.3389\/FRURO.2022.929367\/BIBTEX","article-title":"Long-term outcomes (2 years) after hyaluronic acid therapy for Peyronie\u2019s disease","volume":"2","author":"Cocci","year":"2022","journal-title":"Front Urol"},{"issue":"4","key":"2026090708272364300_ref17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/20905998.2024.2333583","article-title":"Intralesional injection of hyaluronic acid compared with verapamil in acute phase of Peyronie\u2019s disease: a prospective randomized clinical trial","volume":"22","author":"Abdel Fattah","year":"2024","journal-title":"Arab J Urol"},{"key":"2026090708272364300_ref18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41443-025-01223-2","article-title":"Targeting the acute phase of Peyronie\u2019s disease: preliminary experience with Perovial\u00ae, a novel hyaluronic acid formulation","author":"Falcone","year":"2025","journal-title":"Int J Impotence Res 2025"},{"issue":"1","key":"2026090708272364300_ref19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.33393\/AO.2025.3521","article-title":"Effectiveness study of the recombinant enzymes pbserum HIGH in the treatment of pathological scars: a pilot study","volume":"12","author":"Korkunda","year":"2025","journal-title":"AboutOpen."},{"issue":"6","key":"2026090708272364300_ref20","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/0090-4295(83)90210-8","article-title":"Autophotography in evaluation of functional penile disorders","volume":"21","author":"Kel\u00e2mi","year":"1983","journal-title":"Urology."},{"issue":"5","key":"2026090708272364300_ref21","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.eururo.2011.07.053","article-title":"Minimal clinically important differences in the erectile function domain of the international index of erectile function scale","volume":"60","author":"Rosen","year":"2011","journal-title":"Eur Urol"},{"issue":"5","key":"2026090708272364300_ref22","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41443-021-00460-5","article-title":"Peyronie\u2019s disease questionnaire (PDQ): Spanish translation and validation","volume":"34","author":"Garc\u00eda-G\u00f3mez","year":"2021","journal-title":"Int J Impotence Res"},{"issue":"2","key":"2026090708272364300_ref23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.SLA.0000133083.54934.AE","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"2026090708272364300_ref24","doi-asserted-by":"publisher","first-page":"e081123","DOI":"10.1136\/BMJ-2024-081123","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials","volume":"389","author":"Hopewell","year":"2025","journal-title":"BMJ."},{"issue":"2","key":"2026090708272364300_ref25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/J.URPR.2016.04.005","article-title":"Superior cost effectiveness of penile plication vs intralesional collagenase injection for treatment of Peyronie\u2019s disease deformities","volume":"4","author":"Cordon","year":"2017","journal-title":"Urol Pract"},{"issue":"5","key":"2026090708272364300_ref26","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/JSXMED\/QDAF044","article-title":"Injection therapy in the acute phase of Peyronie\u2019s disease: a systematic review of current evidence","volume":"22","author":"Manfredi","year":"2025","journal-title":"J Sex Med"},{"issue":"1","key":"2026090708272364300_ref27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000474800","article-title":"Study of the changes in collagen of the tunica albuginea in venogenic impotence and Peyronie\u2019s disease","volume":"21","author":"Chiang","year":"1992","journal-title":"Eur Urol"},{"issue":"4","key":"2026090708272364300_ref28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/J.JARE.2017.06.004","article-title":"Extracellular matrix alterations in the Peyronie\u2019s disease","volume":"8","author":"Watanabe","year":"2017","journal-title":"J Adv Res"},{"issue":"1","key":"2026090708272364300_ref29","doi-asserted-by":"publisher","first-page":"4653512","DOI":"10.1155\/2017\/4653512","article-title":"Recent pathophysiological aspects of Peyronie\u2019s disease: role of free radicals, rationale, and therapeutic implications for antioxidant treatment\u2014literature review","volume":"2017","author":"Paulis","year":"2017","journal-title":"Adv Urol"},{"issue":"2","key":"2026090708272364300_ref30","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/JSM.12400","article-title":"Acute phase Peyronie\u2019s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation","volume":"11","author":"Mart\u00ednez-Salamanca","year":"2014","journal-title":"J Sex Med"},{"issue":"4","key":"2026090708272364300_ref31","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/BJU.14602","article-title":"Penile traction therapy with the new device \u2018Penimaster PRO\u2019 is effective and safe in the stable phase of Peyronie\u2019s disease: a controlled multicentre study","volume":"123","author":"Moncada","year":"2019","journal-title":"BJU Int"},{"key":"2026090708272364300_ref32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.urology.2017.01.054","article-title":"Clinical experience with penile traction therapy among men undergoing collagenase clostridium histolyticum for Peyronie disease","volume":"104","author":"Ziegelmann","year":"2017","journal-title":"Urology."},{"issue":"12","key":"2026090708272364300_ref33","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/J.JSXM.2020.10.003","article-title":"Outcomes of restoreX penile traction therapy in men with Peyronie\u2019s disease: results from open label and follow-up phases","volume":"17","author":"Joseph","year":"2020","journal-title":"J Sex Med"},{"issue":"6","key":"2026090708272364300_ref34","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/J.JSXM.2019.03.007","article-title":"Efficacy of combined collagenase clostridium histolyticum and restoreX penile traction therapy in men with Peyronie\u2019s disease","volume":"16","author":"Alom","year":"2019","journal-title":"J Sex Med"},{"issue":"10","key":"2026090708272364300_ref35","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/jsxmed\/qdaf213","article-title":"Factors associated with improved curvature outcomes with collagenase clostridium histolyticum for Peyronie\u2019s disease: results from a large prospective series","volume":"22","author":"Cahill","year":"2025","journal-title":"J Sex Med"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/23\/9\/qdag278\/70981115\/qdag278.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/23\/9\/qdag278\/70981115\/qdag278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:27:32Z","timestamp":1788784052000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/doi\/10.1093\/jsxmed\/qdag278\/8787131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdag278","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,5]]},"article-number":"qdag278"}}